Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Says Bio Vitos, a company that sells omega 3 tablets and in which Craven House owns a 24.5% stake, enters into an agreement to buy an 88% stake in Hemcheck Sweden AB, a company focused on detecting hemolyzed blood samples. Hemolyzed means red blood cells in a sample burst, usually rendering it unable to yield a test result. Bio Vitos will pay Hemcheck SEK5.2 million, around £407,249, in cash for business and assets.

Current stock price: $0.35

12-month change: up 59%

Copyright 2023 Alliance News Ltd. All Rights Reserved.